DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$4.36 USD
+0.24 (5.83%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $4.36 0.00 (0.00%) 6:16 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DMAC 4.36 +0.24(5.83%)
Will DMAC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DMAC
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
Best Momentum Stocks to Buy for October 14th
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for October 14th
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Other News for DMAC
DiaMedica Therapeutics (DMAC) Plans to Offer 8.61 Million Common Shares
DiaMedica Therapeutics files to sell 8.61M common shares for holders
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement | DMAC Stock News
DiaMedica (DMAC) Secures $30.1M in Private Placement to Advance Drug Development | DMAC Stock News
DiaMedica Therapeutics to sell 8.606M shares at $3.50 in private placement